Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Subscribe To Our Newsletter & Stay Updated